Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 2/3 3Phase 4 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

pembrolizumab 210Cyclophosphamide 123Nivolumab 108Carboplatin 92fludarabine 82Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 65Biopsy 59atezolizumab 56Cisplatin 55Ipilimumab 50Temozolomide 45Docetaxel 43Azacitidine 42Oxaliplatin 41Lenalidomide 41Pemetrexed 40Fluorouracil 40Rituximab 39Radiotherapy 39Cetuximab 37Capecitabine 37durvalumab 36Cytarabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Megestrol Acetate × 1 year × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡